- Obama not worried about Ebola at upcoming African summit in D.C.
- Obama: ‘We tortured some folks’ after 9/11
- Obama administration asked whole D.C. Circuit to take on major Obamacare case
- Mark Levin: Topple GOP leadership or country will ‘unravel’
- Massachusetts to let police chief deny gun buys to those deemed unfit
- John Kerry condemns attack on Israeli soldiers, kidnapping
- U.S. starts to evacuate American Ebola patients from West Africa: Report
- Geraldo slammed as ‘dummy’ for backing Clinton’s bin Laden claim
- Israeli spokesman: No need to debate who broke the cease-fire
- 35 Palestinians killed; Israeli officer missing
Merck schizophrenia drug approved for 2 new uses
Question of the Day
TRENTON, N.J. (AP) - Merck & Co. said Tuesday its schizophrenia drug Saphris has been approved for two additional uses by the Food and Drug Administration.
The drug was first approved in August 2009 for treating acute schizophrenia episodes in adults and acute mania or manic-depressive behavior in adults with bipolar disorder.
Merck says the FDA now has approved Saphris for ongoing treatment of schizophrenia and for treating acute mania or manic-depressive behavior in adult bipolar patients along with lithium, a mood-stabilizing drug often used to treat mania, or the antiseizure drug valproate.
Saphris carries the FDA’s strongest caution, a black box warning, that it nearly doubles risk of death in elderly patients with dementia.
Like similar drugs, it has many other serious potential risks, including strokes, heart problems, high blood sugar and diabetes, suicide, seizures, fainting, a drop in infection-fighting white blood cells, sedation and impaired thinking, and neuroleptic malignant syndrome, a life-threatening neurological disorder.
Merck has not yet reported sales figures for Saphris, also known as asenapine. That indicates the drug’s quarterly sales have not yet topped Merck’s threshold for reporting individual product sales, $200 million a year or $50 million in a quarter.
Saphris, just launched in the fourth quarter, has lots of tough competition in the lucrative market for antipsychotic medicines, which are approved for treating schizophrenia and bipolar disorder. Rival drugs include Johnson & Johnson’s Risperdal, Eli Lilly & Co.’s Zyprexa, AstraZeneca PLC’s Seroquel, Pfizer Inc.’s Geodon and Bristol-Myers Squibb Co.’s Abilify.
The drugs are widely prescribed for unapproved uses, including other psychiatric conditions and insomnia, significantly boosting their sales.
Last year, antipsychotic drugs brought in $23.25 billion in worldwide sales, according to drug data firm IMS Health.
Saphris was developed by Schering-Plough Corp., which Merck bought last November.
TWT Video Picks
By Orrin G. Hatch
Procedural changes impede the chamber's traditional deliberative function
- Border agents cleared of civil rights complaints from illegal immigrant children
- House GOP resurrects border bill, predicts successful Friday vote
- Ben Carson takes major step toward presidential campaign
- U.N. condemns Israel, U.S. for not sharing Iron Dome with Hamas
- Obama military strategy too weak for future security, panel reports
- Porn-surfing feds blame boredom, lack of work for misbehavior
- Feds raid S.C. home to seize Land Rover in EPA emission-control crackdown
- Ted Nugent slams 'lying freaks' at liberal media: I'm 'doing God's work'
- CRUZ: A tale of two hospitals: One in Israel, one in Gaza
- Islamic militants seize Benghazi as U.S. evacuates Libya
Top 10 U.S. military helicopters
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors